Keywords: antiemetic; bone marrow transplant; chemotherapy; dexamethasone; granisetron; total body irradiation Nausea, retching, and emesis are some of the most common unwanted effects associated with chemotherapy. These treatment side-effects represent a significant concern to the cancer patient.
5-hydroxytrypamine 3 (5-HT
) receptor antagonist that has activity both in the periphery on the abdominal vagal afferents, and centrally on the chemoreceptor trigger zone (CTZ). Emesis occurs when the vomiting center is stimulated by the CTZ or by afferent impulses from the cerebral cortex, gastrointestinal tract, heart, or vestibular apparatus. 4 Several receptor types have been identified in these regions, including dopaminergic, cholinergic, histaminergic, opioid, and serotonergic (5-HT 3 ). 5 Chemotherapy and radiotherapy cause cellular damage, eliciting a release of serotonin from enterochromaffin cells in the intestinal mucosa. Serotonin release also activates 5-HT 3 receptors in the vagal and possibly splanchnic afferent neurons through agonism with resultant stimulation of the CTZ, causing the vomiting reflex. 6 Granisetron controls chemotherapy-induced nausea and vomiting via competitive antagonism of serotonin at the 5-HT 3 receptors. 7 Granisetron is FDA-approved for the prevention of nausea and vomiting associated with initial and repeated courses of emetogenic cancer chemotherapy. Several trials have addressed the antiemetic efficacy of serotonin antagonists for the prevention of irradiation-induced emesis. [7] [8] [9] [10] [11] The controversies that currently exist regarding granisetron use in this patient population include optimal dose and optimal dosing frequency. 11, 12 The main objectives of this trial were to monitor the emetic control of granisetron plus dexamethasone in patients who received chemotherapy regimens containing high-dose CY with or without TBI as a preparative regimen for BM or PBSC transplantation or PBSC mobilization, and evaluate any adverse effects of the combination.
Patients and methods

Study design
This study was a single-center, open-label, prospective trial approved by the Institutional Review Board. Written informed consent was obtained from all patients prior to enrollment. All patients had either a hematologic or oncologic malignancy. Patients were eligible if they were receiving any high-dose chemotherapy preparative regimen containing cyclophosphamide (CY) (у60 mg/kg/day or у1.5 g/m 2 /day) with or without TBI (12 Gy divided over 4 days), followed by BM or PBSC transplantation or PBSC mobilizaton. Additionally, patients had to be 16 years or older and able to record daily nausea levels and daily emetic episodes in a patient diary. Patients with diabetes mellitus or acute central nervous system disease were not enrolled. The endpoints evaluated were control rate for nausea and vomiting throughout the treatment cycle, the need for breakthrough medication for nausea and vomiting, and finally, toxicities associated with granisetron treatment.
Patients
One hundred patients were enrolled in the study. Salient patient demographic and clinical characteristics are shown in Table 1 . The majority of transplants were performed for breast cancer (n = 55) and leukemia (n = 29). Sixty-nine patients had received autologous transplantation while 31 received allogeneic transplantation. Patients were between 21 and 62 years of age. Table 1 Characteristics of the 100 patients enrolled in this study 
Demographic variable n
Preparatory regimens
The conditioning regimens for BMT (n = 31), PBSCT (n = 64), or PBSC (n = ). Most patients who underwent TBI received CY 60 mg/kg i.v. for 2 days (total dose = 120 mg/kg) and thiotepa 5 mg/kg i.v. for 1 day (total dose = 5 mg/kg) plus TBI with 3 Gy every day for 4 days. The various preparatory regimens are shown in Table 1 , and dosages of agents comprising the most commonly used regimens are summarized in Table 2 .
Antiemetic regimen
The protocol was originally designed to use granisetron 10 g/kg, the indicated dose for emetic control. Granisetron was administered i.v. in combination with dexamethasone 10 mg i.v. 30 minutes prior to patients receiving chemotherapy or TBI. However, the first six patients enrolled in the study experienced unacceptable nausea and vomiting while receiving the conditioning regimen and elected to withdraw from the study. As a result, the protocol was amended to standardize antiemetic therapy to granisetron 1 mg i.v. plus dexamethasone 10 mg i.v. daily. Granisetron 1 mg i.v. piggyback (IVPB) plus dexamethasone 10 mg IVPB was administered starting 30 min prior to the first dose of chemotherapy and/or TBI. This treatment was repeated daily and continued for 24 h after the last dose of chemotherapy or TBI. For breakthrough nausea and/or emesis, an additional dose of granisetron 1 mg IVPB was given as needed once per 24 h. If the granisetron was ineffective, prochlorperazine 10 mg IVPB plus diphenhydra- Table 2 Most commonly used preparatory regimens mine 25 mg IVPB, lorazepam 2 mg IVPB, or haloperidol 2 mg IVPB plus diphenhydramine 25 mg IVPB was made available to the patients every 4 h as needed.
Drug discontinuation criteria
Treatment with granisetron was discontinued in patients who developed unacceptable toxicities, had an allergic reaction, had insufficient antiemetic control, were unable to record data in the patient diaries, or who requested that treatment be terminated.
Response criteria
Response was defined by the number of vomiting episodes over a 24-h period, during chemotherapy administration and/or TBI. Vomiting, sometimes called emesis, is the mechanical expulsion of gastric contents by coordinated respiratory and abdominal muscles. Each vomiting episode experienced by the patient was recorded by the patient and the nurse. Instances of vomiting separated by 1 min or more were counted as individual vomiting episodes. Complete response was defined as no episode of vomiting in any 24-h period and no rescue antiemetic needed. A major response was defined as one or two episodes of vomiting in any 24-h period with or without the addition of rescue antiemetics. A minor response was defined as three to five vomiting episodes in any 24-h period with or without the addition of rescue antiemetics. Failure to respond was defined as more than five vomiting episodes in any 24-h period over the treatment cycle.
Patient diary data
Each enrolled patient was provided a diary that was to be completed each day the patient received chemotherapy or a combination of chemotherapy and TBI, and continued until 24 h after the last treatment. The diary record consisted of 24-h total oral fluid intake, the number of vomiting episodes per day, a visual analog scale to evaluate morning and evening nausea, and a questionnaire to assess patient perception of treatment outcomes. The record of daily oral fluid intake and the number of vomiting episodes was compared with the patient chart and nursing documentation. The standard visual analog scale used to assess nausea ranged from 0 cm (no nausea) to 10 cm (the worst possible nausea). The patient questionnaire assessed the patients' daily routine and diet (how well they were able to eat and how well they felt with treatment) and the effectiveness of the antiemetic with the current chemotherapy regimen (compared with previous chemotherapy experience); also, any unwanted effects of the antiemetic medication were assessed.
Results
Acute emesis and nausea
Information on oral fluid intake and vomiting was obtained from the patient diary, nursing notes, and protocol tracking
Bone Marrow Transplantation forms. Data from the three sources were generally consistent. However, where any discrepancies were found, data from the nurse's notes were used for analysis. Patient compliance in completing the diaries was excellent, ie 98%. The mean number of days patients received granisetron was 5 (1-8). The mean oral intake per day was 1177 ml (180-6665 ml). The mean emetic episodes per day from 0 to 12 h and 12 to 24 h after treatment were 0.31 (0-8) and 0.17 (0-4), respectively (mean, 0.24 per day). The mean number of rescue doses required per day during 0 to 12 h and 12 to 24 h were 0.48 (0-8) and 0.33 (0-4), respectively (mean, 0.40 per day). Based on a total of 456 patient days, response was complete on 216 days (47%), major on 222 (49%), minor on 14 (3%), and failure to respond on 4 (1%). The mean morning and evening nausea scores reported on the visual analog scale were 1.30 cm (0-10 cm) and 1.68 centimeters (0-10 cm), respectively. The efficacy data are summarized in Table 3 . When the emetic control rate was analyzed by day, a sustained effect was demonstrated for the study duration ( Figure 1 ). The majority of patients (91-98%) achieved either a complete response or a major response during the first 4 days of the study, and all patients achieved this level of response over the last 4 days.
Patient diary questionnaire
On a daily basis, 57% of patients were able to eat and get out of bed without any problem. Thirty-four percent experienced some nausea and difficulty eating but would get out of bed, while 9% vomited almost everything and stayed in bed. The patients' perception of antinausea effectiveness was either very effective (59%), somewhat effective (36%), or not effective (5%). Patient diary questionnaire data are summarized in Table 4 . 
Toxicities
Adverse effects are also presented in Table 4 . The majority of toxicities were minimal, with headache, diarrhea, and constipation reported in 20%, 15%, and 12% of patients, respectively. Two patients required discontinuation of granisetron and dexamethasone because of excessive nausea and vomiting during their conditioning regimen.
Patient withdrawals
The first six patients enrolled in the study received granisetron at a dose of 10 g/kg. These patients experienced unacceptable nausea and vomiting subsequent to administration of CY and elected to withdraw from the study on day 4. However, data were collected and analyzed for these six patients. Based on the experience of these patients, the protocol was amended to standardize antiemetic therapy to granisetron 1 mg i.v. plus dexamethasone 10 mg i.v. daily. After the granisetron dose adjustment was implemented, six additional patients withdrew from the study. Two patients withdrew on day 2 because of excessive nausea and vomiting, and two others withdrew on day 4 because they were unable to record data in their patient diaries. The data for these four patients were also included in the analysis. The two remaining patients withdrew from study prior to receiving therapy and therefore provided only demographic information. One of the two patients withdrew before receiving the preparative regimen and antiemetic therapy because of a severe migraine headache. The second patient was enrolled in the study, but developed a severe infection before treatment and subsequently had transplantation delayed.
Discussion
Although the 5-HT 3 -receptor antagonists have demonstrated significant activity in patients undergoing chemotherapy, the challenges presented in patients undergoing high-dose chemotherapy, with or without TBI, in BMT or PBSC transplantation still remain a significant concern. These treatment modalities are highly emetogenic, and although the antiemetic utility of corticosteroids, such as dexamethasone, in combination with other agents is well established, 13 few trials have evaluated combinations of 5-HT 3 -receptor antagonists and dexamethasone in this clinical setting. This single-center, open-label, prospective trial was conducted primarily to evaluate the efficacy and safety of granisetron plus dexamethasone in BMT/PBSCT patients conditioned with CY-containing regimens with or without TBI.
The results of this trial demonstrated that granisetron 1 mg i.v. plus dexamethasone 10 mg i.v. daily was effective in the prophylactic management of nausea and vomiting in patients who were being prepared for BMT or PBSC transplantation, or PBSC mobilization. The preparatory regimens contained high-dose CY with or without TBI. A complete response to treatment with granisetron and dexamethasone was noted on 47% of 255 patient-days, a major response was noted on 49% of days (complete response + major response = 96%), a minor response on 3% of days, and failure to respond on only 1% of the days. The clinical effectiveness of the combination of granisetron and dexamethasone was also reflected in the patients' perception of treatment success as evaluated by means of the questionnaire in the patient diary. Nearly 60% of patients reported the treatment to be very effective, and only 5% reported that treatment was not effective. The study patients had received emetogenic chemotherapy in the past, and 75% had experienced nausea and 12% had prior anticipatory nausea and vomiting. It should be noted that, overall, the patients were very involved in participating in the study and kept accurate diaries. As mentioned above, the compliance rate for completion of the patient-questionnaire diary was approximately 98%. Only two patients were withdrawn from the study because of failure to complete the patient diary. The high compliance rate for completion of the patient diary was largely due to nursing support as well as a having a designated pharmacist who visited the patients daily to assess completion of the forms. Nursing records were also reviewed at this time. Any discrepancies between the nurses' and patients' reports were resolved on a daily basis, and patient education relative to completing the diary was provided if necessary.
The combination of granisetron plus dexamethasone used in this study was equally effective in both subgroups of patients, ie, those who received chemotherapy alone, and those who received chemotherapy and TBI. We recently reported the results of 26 evaluable patients from this study who had received high-dose chemotherapy with TBI.
14 For 25 patients who completed 186 evaluable treatment days, a complete response to treatment with granisetron and dexamethasone was noted on 50% of patient-days, a major response on 48%, and a minor response on 2%; no failures were recorded. These results were very similar to those for the total population described here. Impact of this treatment regimen on patient perception of treatment outcomes, as well as the adverse events profile, was also similar in the TBI subgroup compared with the entire study population. Granisetron was well tolerated in the total patient population. The major adverse effects reported were headache (20%), diarrhea (15%), and constipation (12%), none of which caused any patient to withdraw from the trial.
Few trials have investigated the efficacy of 5-HT 3 -receptor antagonists in BMT and PBSC patients, but increasing evidence supports the use of these agents for antiemetic prophylaxis in patients undergoing preparatory regimens. In several studies, i.v. granisetron and i.v. ondansetron have been shown to produce complete or major responses in 67% to 87% of BMT/PBSC patients. 8, 15, 16 In a study that employed conditioning regimens similar to those used in this study, 8 granisetron was evaluated as a single-agent antiemetic compared with metoclopramide-based treatments. The 58 patients, who were being conditioned for stem cell transplantation, had received high-dose chemotherapy with or without TBI. Granisetron was significantly more effective (87.1% vs 37.0%, P Ͻ 0.001) than the standard antiemetic regimens used. Reported adverse events were few and not serious. We have augmented this work with a trial of granisetron plus dexamethasone in a similar patient population. Our experience in patients being conditioned for marrow or PBSC transplantation suggests that granisetron 1 mg i.v. plus dexamethasone 10 mg i.v. administered 30 min prior to marrow ablative therapy is effective and well tolerated in patients receiving high-dose cyclophosphamide-containing regimens with or without TBI. Moreover, the patients' perceptions of treatment outcome as measured by daily routine and eating habits were generally favorable, and adverse effects were minimal. Additional research is required to identify the role of dexamethasone in patients Bone Marrow Transplantation receiving conditioning regimens and to explore the use of oral 5-HT 3 -containing antiemetic regimens for managing nausea and vomiting in this population.
